10,180 Shares in TG Therapeutics, Inc. $TGTX Purchased by Great Lakes Advisors LLC

Key Points

• Great Lakes Advisors LLC has acquired a new stake in TG Therapeutics, purchasing 10,180 shares valued at approximately $401,000 in the first quarter.
• Goldman Sachs has upgraded TG Therapeutics to a "hold" rating with a price target of $37.00, and analysts have a consensus rating of "Moderate Buy" with a target of $46.25.
• Despite a significant year-over-year revenue increase of 92.1%, TG Therapeutics reported earnings per share of $0.17, missing analyst expectations of $0.32.

Great Lakes Advisors LLC acquired a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,180 shares of the biopharmaceutical company's stock, valued at approximately $401,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in TGTX. Allspring Global Investments Holdings LLC lifted its holdings in TG Therapeutics by 54.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 23,775 shares of the biopharmaceutical company's stock valued at $898,000 after purchasing an additional 8,338 shares in the last quarter. New York State Teachers Retirement System raised its position in shares of TG Therapeutics by 175.0% in the first quarter. New York State Teachers Retirement System now owns 120,364 shares of the biopharmaceutical company's stock valued at $4,746,000 after buying an additional 76,600 shares during the last quarter. Crossmark Global Holdings Inc. acquired a new position in shares of TG Therapeutics in the first quarter valued at approximately $226,000. GAMMA Investing LLC raised its position in shares of TG Therapeutics by 77.7% in the first quarter. GAMMA Investing LLC now owns 4,543 shares of the biopharmaceutical company's stock valued at $179,000 after buying an additional 1,986 shares during the last quarter. Finally, Braun Stacey Associates Inc. raised its position in shares of TG Therapeutics by 13.5% in the first quarter. Braun Stacey Associates Inc. now owns 502,650 shares of the biopharmaceutical company's stock valued at $19,819,000 after buying an additional 59,845 shares during the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.

TG Therapeutics Stock Performance

Shares of NASDAQ:TGTX traded up $0.57 on Thursday, reaching $32.61. 1,684,017 shares of the company's stock were exchanged, compared to its average volume of 2,002,512. The firm has a market capitalization of $5.17 billion, a price-to-earnings ratio of 88.14 and a beta of 1.88. TG Therapeutics, Inc. has a fifty-two week low of $21.16 and a fifty-two week high of $46.48. The business's 50-day moving average is $32.01 and its two-hundred day moving average is $35.67. The company has a quick ratio of 2.96, a current ratio of 3.86 and a debt-to-equity ratio of 0.89.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). The business had revenue of $141.15 million for the quarter, compared to analyst estimates of $147.76 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The firm's revenue for the quarter was up 92.1% on a year-over-year basis. During the same period last year, the company posted $0.04 earnings per share. TG Therapeutics has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Insider Buying and Selling at TG Therapeutics

In related news, Director Sagar Lonial sold 20,852 shares of the stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $32.24, for a total value of $672,268.48. Following the sale, the director owned 94,061 shares of the company's stock, valued at $3,032,526.64. This trade represents a 18.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 10.64% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on TGTX shares. The Goldman Sachs Group raised shares of TG Therapeutics to a "hold" rating and set a $37.00 price objective for the company in a research report on Thursday, July 10th. B. Riley boosted their price objective on shares of TG Therapeutics from $53.00 to $55.00 and gave the company a "buy" rating in a research report on Wednesday. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $48.00.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.